New research suggests that the use of dronedarone (Multaq) could be dangerous in permanent atrial fibrillation cases due to cardiovascular and mortality risks. The analysis of data collected during the now halted PALLAS trial revealed a “2.29-fold excess in stroke, myocardial infarction, systemic embolism and death from cardiovascular causes combined among patients taking the rhythm [...]
